Purchase this article with an account.
Harpal Sandhu, Demetrios G Vavvas; Eplerenone fails to treat central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6378.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of the mineralocorticoid receptor antagonist eplerenone in patients with active central serous chorioretinopathy (CSR).
Retrospective case series of three patients treated with eplerenone for central serous chorioretinopathy. All patients were assessed with a full eye exam and spectral domain optical coherence tomography (SD-OCT) at each visit.
Three eyes in three patients were treated with eplerenone 25 mg or 50 mg daily by mouth. All patients had decreased vision secondary to active CSR. Follow up ranged from three to 12 months. Visual acuity (VA) at the beginning of treatment ranged from 20/32 to 20/60 (mean VA 0.42). Visual acuity at one month was not significantly different (mean VA 0.49, p = 0.43), nor at the end of follow up (mean VA 0.43, p = 0.42). Central macular thickness did not change significantly from pre-treatment (mean 474 microns) to month one (mean 429 microns, p = 0.23), nor did it change significantly at the end of the follow-up period (mean 431 microns, p = 0.32).
Eplerenone neither reduced central macular thickness nor improved vision in this cohort of patients with central serous chorioretinopathy. More research is needed to evaluate fully the efficacy of eplerenone for this indication.
This PDF is available to Subscribers Only